SGLT2-inhibitors are effective and safe in the elderly: The SOLD study

• প্রধান লেখক: Maria Elena Lunati (লেখক), Vincenzo Cimino (লেখক), Alessandra Gandolfi (লেখক), Matteo Trevisan (লেখক), Laura Montefusco (লেখক), Ida Pastore (লেখক), Camilla Pace (লেখক), Nazarena Betella (লেখক), Giuseppe Favacchio (লেখক), Monica Bulgheroni (লেখক), Loredana Bucciarelli (লেখক), Giulia Massari (লেখক), Cristina Mascardi (লেখক), Angela Girelli (লেখক), Paola Silvia Morpurgo (লেখক), Franco Folli (লেখক), Livio Luzi (লেখক), Marco Mirani (লেখক), Basilio Pintaudi (লেখক), Federico Bertuzzi (লেখক), Cesare Berra (লেখক), Paolo Fiorina (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Elsevier, 2022-09-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Background and aims: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) may have important benefits for the elderly with type 2 diabetes (T2D), however some safety concerns still limit their use in patients over 70 years of age. The SOLD study (SGLT2i in Older Diabetic patients) is a multicenter st...